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Coronary artery inﬂammation is a critical process in the pathogenesis of myocardial infarction (MI). The chemokine
CCL5/RANTES (regulated upon activation,normalTcells expressed andsecreted) isexpressed inadvancedatheroscleroticlesions.
Functional polymorphisms of the RANTES gene can, therefore, be involved in the pathogenesis of coronary artery disease. We
examined the association of polymorphisms in the RANTES gene with myocardial infarction in Slavonic populations of Czech
and Russian origin. A total of 467 post-MI patients and 337 control subjects were genotyped for RANTES promoter G-403A
(rs2107538) and intron 1.1T/C (rs2280789) variants by PCR-SSP. Both RANTES genotypes and allele frequencies did not diﬀer
between case and control groups. Haplotype-based analysis also failed to reveal an association between MI and investigated
markers. Strong linkage disequilibrium was detected between particular RANTES alleles. The data do not support an association
between RANTES G-403A polymorphism and MI, as reported previously.
1.Introduction
Atherosclerosis is a pathological process that takes place
in the major arteries and represents one of the causes of
myocardial infarction (MI), ischemic stroke, and peripheral
artery disease. Atherosclerosis, a multifactorial condition
determined by environmental as well as genetic factors,
has a strong inﬂammatory component [1] characterised
by deregulation of gene expression in macrophages within
atherosclerotic plaques, together with local overproduc-
tion of cytokines. Among those, chemokines (chemotactic
cytokines)havealsobeenimplicatedinatherosclerosisonthe
basis of clinical studies and animal disease models [2].
The chemokine RANTES, also known as CC chemokine
ligand (CCL5),is involved in the activation and proliferation
of T-lymphocytes and is considered as a major chemokine
implicatedinboththeacuteandchronicphasesofinﬂamma-
tion. Tissue RANTES expression is diﬀerentially regulated:
in atherosclerosis, RANTES mRNA has been detected in the
lymphocytes, macrophages, myoﬁbroblasts, and endothelial
cells of human arteries undergoing accelerated atheroscle-
rosis but not in normal coronary arteries [3]. RANTES
was also found deposited on activated endothelium or
murine atherosclerotic carotid arteries [4]. Platelets, which
are also implicated in the atherosclerotic process including
myocardial infarction (MI), are known to store RANTES in
intracellular granules in the basal state and to secrete it when
stimulated with thrombin [5].
Single nucleotide polymorphisms in the RANTES gene
promoter and intronic region have been described: C-28G,
G-403A (relative to transcription start site), polymorphism
in intron 1 (In1.1 T/C), and in the 3 untranslated regions2 Mediators of Inﬂammation
[6, 7]. The case-control study investigating RANTES SNP G-
403A in Germans associated this SNP with a susceptibility
to coronary atherosclerosis [8]; in another study, in Hun-
garians, however, this association was not signiﬁcant [9].
That RANTES polymorphisms may play a role in cardiac
pathology was also suggested by a report enrolling patients
with type 2 diabetes mellitus and end stage renal disease
[10]: the carriage of either RANTES -403 G/A or intronic
polymorphism (In1.1 T/C) was associated with all-cause
mortality due mainly to cardiac events.
Concerning the eﬀect of these SNPs on RANTES expres-
sion, an increased gene expression was linked with the minor
allele in the RANTES gene at the nucleotide position -
403 and -28 [11, 12]. However, in vitro functional data are
more important for RANTES intronic polymorphism T/C:
In1.1C allele or haplotypes that include this variant showed
a strong dominant association with rapid progression to
AIDS [7]. Furthermore, RANTES gene polymorphisms were
associated with the outcomes of HCV and HBV infections
[13, 14]. By analogy, atherosclerotic lesions, the underlying
cause of coronary artery disease (CAD) and MI, represent
a series of highly speciﬁc cellular and molecular events of
the inﬂammatory response [1]. Despite convincing evidence
for a role of the RANTES polymorphisms in diﬀerent
inﬂammatory diseases, their role in CAD requires further
investigation.
Given the inﬂammatory component of coronary athero-
sclerosis and the lack of case-control investigations of more
than one RANTES polymorphism in MI, this study exam-
ined the relationship between two RANTES polymorphisms
(promoter G-403A, intron1.1 T/C) with their haplotypes
and myocardial infarction. In agreement with genetic epi-
demiologyprinciples, our “replication” study comprised two
population cohorts (Czech, Russian) diﬀering in ethnicity
from those populations in which the RANTES gene was
investigated previously (Hungarian, German).
2.Materialsand Methods
2.1. Study Population. A total of 804 unrelated Caucasian
individuals were enrolled into this case-control study, of
which 467 were MI cases and 337 healthy controls subjects.
Twopopulationgroupswererecruited:(1)Czech(Olomouc)
with 223 MI patients and 140 control subjects and (2)
Russian (Novosibirsk) with 244 cases and 197 controls from
the MONICA project register. Table 1 shows demographic
and clinical characteristics of the study groups.
The diagnosis of MI was made according to the criteria
recommended by international consensus [15]. MI events
were deﬁned on the basis of electrocardiographic (ECG)
changes and biomarker (troponin, alternatively creatine-
kinase) measurements. Local research ethics committees
approved the studies and the subjects provided written
informed consent for use of samples in these genetic studies
and anonymous publication of the summary data.
2.2. SNP Genotyping. Genotype analysis for the RANTES
SNPs was performed by polymerase chain reaction with
sequence-speciﬁc primers(PCR-SSP).The investigated SNPs
included RANTES promoter G-403A (rs2107538) and
RANTES intron 1.1 T/C (rs2280789). The sequences of
speciﬁc primers were as follows: allele G, forward 5  ATG
GAT GAG GGA AAG GAG G 3 ,a l l e l eA ,f o r w a r d :5   CAT
GGA TGA GGG AAA GGA GA 3 , constant reverse: 5 
TTC TCT GCT GAC ATC CTT AG 3 ;i n t r o n1 . 1T / C ;
allele T, forward: 5  CCT GAT CAG TTT TTC TGT CTT
T3  , allele C, forward: 5  CCT GAT CAG TTT TTC TGT
CTT C 3 , constant reverse: 5  TGT GAG CTA CTC ATG
ACT AC 3 . The internal control primers and conditions
for PCR were adopted from a “Phototyping” methodology
[16].
2.3. Statistical Analysis. Calculations were performed using
the SPSS v.13.0 (SPSS Inc, Chicago, IL). Categorical data
of the study population was reported as frequencies and
percentage, the continuous data as means with standard
deviation. The distribution of the RANTES genotypes and
alleles were analyzed using the Pearson’s contingency table
χ2-test. Odds ratios and 95% conﬁdence interval (CI) were
estimated. A multiple variable logistic regression model
was used to estimate the association between genotype and
disease. Statistical signiﬁcance was accepted at P<. 05.
Haplotype analysis was performed using an accelerated
expectation-maximization algorithm (software ARLEQUIN,
version 3.000).
3.Results
3.1. Distribution of RANTES Polymorphisms in Patients
and Control Subjects. First, we evaluated distribution of
RANTES polymorphisms in patients and control subjects
(for genotype and allele frequencies see Table 2). Out of
467 and 337 individuals in each group, the genotype data
f o rR A N T E Si n t r o n1p o l y m o r p h i s mw a sa v a i l a b l ei n4 6 5
patients and 330 controls as 2 patients and 7 control
samples failed to amplify; the overall failure rate was only
1.2% (9/804). Both the RANTES -403 and RANTES In1.1
genotypes were distributed as expected from the Hardy-
Weinberg equilibrium (P>. 05).
In both the Czech and Russian populations, there were
no signiﬁcant diﬀerences in the frequencies of genotypes
between the MI cases and controls for the two RANTES
polymorphisms studied. The distribution of RANTES geno-
types was similar also when both populations were eval-
uated together (Table 2), except that the frequency of CC
homozygous genotype in MI patients (2.8%) was higher
than observed in controls (0.9%), but this diﬀerence did not
achieve a statistical signiﬁcance.
Further, we carried out standard allelic association anal-
ysis: minor allele frequencies for the two polymorphisms
were calculated, and the odds ratio and 95% conﬁdence
interval for the RANTES -403A and RANTES In1.1C were
0.996 (95% CI 0.740–1.340) and 1.054 (95% CI 0.759–
1.464), respectively, (P>. 05 in both cases). Also, when
evaluating carrier status for -403A and In1.1C alleles, there
werenosigniﬁcant diﬀerencesbetweenMIcasesandcontrolsMediators of Inﬂammation 3
Table 1: Demographic and clinical characteristics of the study groups (MI patients and control subjects).
Case group RU Control group RU Case group CZ Control group CZ
Number of subjects 244 197 223 140
Caucasians (%) 244 (100%) 197 (100%) 223 (100%) 140 (100%)
Mean age (years)∗ 56.6 ±9.74 3 .6 ±7.45 5 .0 ±8.33 5 .7 ±7.4
Gender (males/females) 167/77 87/110 186/37 87/53
Current smokers (%) 88 (97.7%)a 123 (63.7%)b 64 (31.7%)c n.a.
Total cholesterol (mmol/l) 6.2 ±1.35 .2 ± 1.35 .7 ±1.15 .9 ±1.0
HDL (mmol/l) 1.2 ±0.31 .3 ± 0.41 .1 ±0.31 .4 ±0.4
Triglycerides (mmol/l) 1.7 ±0.81 .1 ± 0.72 .4 ±1.61 .9 ±1.1
LDL (mmol/l) n.a. 3.1 ± 1.33 .4 ±1.03 .7 ±0.9
∗Mean ± Standard Deviation for continuous variable.
aSmoking habit was available in 90 (36.9%) patients.
bSmoking habit was available in 193 (98%) subjects.
cSmoking habit was available in 202 (91%) subjects.
RU: Russian, CZ: Czech, HDL: high density lipids, LDL: low density lipids, n.a.: not available.
Table 2: RANTES promoter and intron polymorphisms: genotype and allele distribution in Slavonic patients with MI and control
populations.
RANTES promoter G-403A RANTES intron 1.1 T/C
Case (n = 467) Control (n = 337) P value Case (n = 465) Control (n = 330) P value
GG (%) 310 (66.4) 224(66.5)
.709a
TT (%) 354 (76.1) 248 (75.2)
.126a GA (%) 135 (28.9) 101 (30) TC (%) 98 (21.1) 79 (23.9)
AA (%) 22 (4.7) 12 (3.6) CC (%) 13 (2.8) 3 (0.9)
G allele (%) 755 (80.8) 549 (81.5) .754b T allele (%) 806 (86.7) 575 (87.1) .791b
A allele (%) 179 (19.2) 125 (18.5) C allele (%) 124 (13.3) 85 (12.9)
aP value from χ2test with 2df.
bP value from χ2test with 1df.
(P = .97, df = 1 for AA+AG versus GG -403 genotypes; and
P = .75, for CC+CT versus TT In1.1 genotypes).
3.2. Relationship between RANTES Gene Variants, Demo-
graphic Factors, and Myocardial Infarction. Next, thepatients
were divided into subsets according to gender and age at the
time of the 1st myocardial infarction, and univariate analyses
were performed. There was no diﬀerence in genotype
distribution when male and female cases were compared
with controls of appropriate gender separately (RANTES G-
403A: P = .863 for males and P = .789 for females; RANTES
In1.1 T/C: P = .148 for males and P = .744 for females). No
diﬀerences in genotype and alleles frequencies (-403A and
In1.1C)wereobservedbetweenthepatientsstratiﬁed accord-
ing to the age of MI onset (>50yr and <50yr) (Table 3).
Subsequently, multivariate logistic regression analysis
was performed, adjusting for age and gender. Also, in the
logistic regression analysis, no evidence for association was
found between the polymorphisms of the RANTES gene and
the risk for MI in our study population (Table 4).
3.3. Identiﬁcation and Comparison of RANTES Haplotypes
in the Slavonic Population. The frequencies of combined
genotypes and haplotypes of the RANTES G-403A/In1.1T/C
loci are listed in Table 5. The combined genotypes GGTT
and AGTC were the most frequent (case/control group
62.3%/64% and 18%/18.4%, resp.). No statistically signif-
icant diﬀerence was observed in the RANTES combined
genotypes between the cases and controls (χ2 = 4.53,
df = 7, P = .717). However, we detected strong linkage
disequilibrium between the two less common alleles for two
RANTES SNPs: allele A of the RANTES promoter G-403A
and C allele of the RANTES intron 1 T/C (D  = 0.83 for
patients with MI and D  = .88for control group; P<10−6 in
both cases).
4.Discussion
This case-control study aimed at exploring the association
between coronary atherosclerosis manifested by myocar-
dial infarction and two functional polymorphisms in the
RANTES (CCL5) gene, the product of which is involved
in atherosclerotic inﬂammation. In this two-population
replication study, no signiﬁcant diﬀerences in the distribu-
tion of RANTES G-403A, and In1.1 T/C single nucleotide
polymorphisms wereobservedbetweenpatientswithMIand
the control groups. Further, when the subjectswere stratiﬁed
according to their gender and age at the ﬁrst MI episode,
no signiﬁcant relationships were revealed. Thus, ourﬁndings
do not support the previous report of association between
RANTES promoter G-403A polymorphism and coronary
artery disease [8]. Importantly, our report represents the4 Mediators of Inﬂammation
Table 3: RANTES genotype frequencies in MI patients and cases subdivided according to age at the ﬁrst MI episode.
RANTES SNPs RANTES genotypes
≤50 years >50 years
MI (n = 159) control (n = 289) P value MI (n = 308) control (n = 47) P value
G-403A(%)
GG 100 (62.9) 189 (65.4)
.87
210 (68.2) 34 (72.3)
.85 GA 53 (33.3) 90 (31.1) 82 (26.6) 11 (23.4)
AA 6 (3.8) 10 (3.5) 16 (5.2) 2 (4.3)
MI (n = 158) control (n = 284) P value MI (n = 306) control (n = 45) P value
In1.1 T/C(%)
TT 122 (77.2) 215 (75.7)
.21
232 (75.8) 32 (71.1)
.33 TC 31 (19.6) 66 (23.2) 66 (21.6) 13 (28.9)
CC 5 (3.2) 3 (1.1) 8 (2.6) 0
Table 4: Multivariate logistic regression analysis of the MI risk
according to RANTES genotypes in the Slavonic population
adjusted for age and gender.
Polymorphisms Genotype OR 95% CI P value
RANTES -403 G/A AA versus
GA+GG 1.171 0.373–3.673 .79
RANTES In1.1T/C CC versus
TC+TT 2.747 0.451–16.715 .27
ﬁrst investigation of two linked RANTES polymorphisms
and speciﬁcally analysis of their haplotypes in the Slavonic
population.
Previous studies associating RANTES SNPs with coro-
nary atherosclerosis [8, 9]c o n c e n t r a t e do nt h eR A N T E S
promoter polymorphism (G-403A) and did not explore the
relationship between cardiovascular symptomatology and
further polymorphisms in the RANTES gene, including its
intronic variant In1.1T/C. Only B¨ oger et al. [10], who inves-
tigated RANTES promoter and intronic polymorphisms in
type2 diabetes/end stagerenal disease, reported thatpatients
carrying the RANTES-403A or In1.1C allele had higher
all-cause mortality risk, mainly due to cardiac events. We,
however,cannotcomparetheirdatawithourresults,because
Boger’s study did not include a control population (healthy
controls) and also estimated the eﬀect of genetic predictors
of survival and functional polymorphisms on mortality in
another disease condition.
Ad i ﬀerence in exact disease phenotypes may be another
less prominent, but still relevant factor explaining the
discrepancy between our negative data and the ﬁrst case-
control association study on RANTES, which showed a
trend indicating a higher risk for coronary artery disease for
Hungarian patientswith the -403Aallele [9].The population
size of their cohort and our Slavonic population was
identical; however, the Hungarian study enrolled patients
with severe coronary artery disease (CAD) not necessarily
presenting with MI.
The LURIC (the Ludwigshafen risk and cardiovascular
health) study was the second to report the association
for -403A allele [8]. We speculate that the deviation of
distribution of G-403A genotypes from that expected from
the Hardy-Weinberg equilibrium in controls of the LURIC
study, may contribute to the discrepancy between LURIC
and our ﬁndings concerning the relationship ofthe RANTES
-403A variant and CAD. Though smaller in number of
enrolled subjects, our Czech and Russian groups were
strongly compliant with the HWE.
Strong linkage disequilibrium was observed throughout
the RANTES gene, and in particular between the alleles at
the four most polymorphic sites, -403, -28, In1.1, and 3 222
[7]. The In 1.1T occurs in combinations with -403G in 77%
of genotyped European Americans (5% had In1.1T/-403A
haplotype), and allele In1.1C occurred with frequencies of
0.14 in European Americans, 0.20 in African Americans, and
0.34 in Asians. In the present study, we revealed similar allele
In1.1C frequencies in our investigated Slavonic populations
as inEuropeanAmericans, and conﬁrmedstronglinkagedis-
equilibrium between two less common variants at RANTES
-403 and In 1.1 loci.
The functional eﬀect of particular SNPs in the RANTES
gene and the level of its expression and/or secretion which
may provide a mechanism explaining the observed associa-
tionwithCAD[8],isstillcontroversial[7,11,12,17,18].The
-403A allele has been associated with increased transcription
of the RANTES gene, and further evidence of the functional
importance of this variant is provided by a signiﬁcant risk
of atopic dermatitis [19], atopy, and asthma in adults [20]
but without studying the eﬀect of the -28 or In1.1 loci.
Otherstudiesshowed anupregulatory roleforthe-28G allele
but did not demonstrate upregulation for -403A [12, 18].
Another study demonstrated that RANTES In1.1C alelle was
associated with reduced RANTES expression, -28G allele
had a moderate role for expression and -403A allele was
not regulatory [7]. Discrepant data on correlations between
RANTES polymorphisms and level RANTES expression for
other common inﬂammatory and chronic infection diseases
support the need for further investigation of the relationship
between variability in RANTES gene and its expression.
In conclusion,in this two-population-based case-control
study, no signiﬁcant diﬀerence was detected in the distribu-
tion of two RANTES gene polymorphisms between healthy
controls and patients with myocardial infarction, indicating
the lack of association between coronary atherosclerosis
and RANTES single nucleotide polymorphisms. Our results,
therefore, do not support a major involvement of RANTES
G-403A and In1.1 T/C polymorphisms in genetic predispo-
sition to myocardial infarction.Mediators of Inﬂammation 5
Table 5:Thefrequencies ofhaplotypes (estimated) andcombinedgenotypes oftwoRANTES singlenucleotide polymorphismsG-403A and
In 1.1 T/C in the Slavonicpopulation.
HaplotypesG-403A/In1.1 T→CC a s e 2 n = 904 Control 2n = 634
AC 0.112 0.114
AT 0.079 0.073
GC 0.017 0.012
GT 0.789 0.800
Combined genotypes
AATT 0.006 0.054
AATC 0.018 0.017
AGTT 0.126 0.117
AGTC 0.180 0.184
AACC 0.013 0.013
AGCC 0.004 0.003
GGTT 0.623 0.640
GGTC 0.028 0.019
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